Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source—a series of four cases

We present four cases with Gram-positive bacteremia (pathogens: MRSA n  = 1 , Enterococcus spp. n  = 3) due to an intravascular source (left ventricular assist device: n  = 2, transfemoral aortic valve implantation n  = 1, prosthetic aortic valve: n  = 1) where no curative treatment was available. T...

Full description

Saved in:
Bibliographic Details
Published in:Infection 2021-02, Vol.49 (1), p.181-186
Main Authors: Hitzenbichler, Florian, Mohr, Arno, Camboni, Daniele, Simon, Michaela, Salzberger, Bernd, Hanses, Frank
Format: Article
Language:English
Subjects:
Antibiotics
Aorta
Aortic valve
Bacteremia
Case Report
Case reports
Drug resistance
Endocarditis
Family Medicine
General Practice
Gram-positive bacteria
Heart
Heart valves
Infectious Diseases
Internal Medicine
Medicine
Medicine & Public Health
Patients
Prostheses
Side effects
Transplants & implants
Ventricle
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c523t-5ba1080bc8cad0b37804cb0d0a35cf6e6811369b1d494072e0525c3c8f3159a93
cites cdi_FETCH-LOGICAL-c523t-5ba1080bc8cad0b37804cb0d0a35cf6e6811369b1d494072e0525c3c8f3159a93
container_end_page 186
container_issue 1
container_start_page 181
container_title Infection
container_volume 49
creator Hitzenbichler, Florian
Mohr, Arno
Camboni, Daniele
Simon, Michaela
Salzberger, Bernd
Hanses, Frank
description We present four cases with Gram-positive bacteremia (pathogens: MRSA n  = 1 , Enterococcus spp. n  = 3) due to an intravascular source (left ventricular assist device: n  = 2, transfemoral aortic valve implantation n  = 1, prosthetic aortic valve: n  = 1) where no curative treatment was available. These patients received indefinite, chronic suppressive (palliative) therapy with dalbavancin (500 mg weekly or 1000 mg biweekly regimens). Outcomes and clinical characteristics are described; treatment was effective in suppression of bacteremia in all patients over several months (range: 1 to more than 12 months), we observed no relevant side effects.
doi_str_mv 10.1007/s15010-020-01526-0
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7850995</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2484418622</sourcerecordid><originalsourceid>FETCH-LOGICAL-c523t-5ba1080bc8cad0b37804cb0d0a35cf6e6811369b1d494072e0525c3c8f3159a93</originalsourceid><addsrcrecordid>eNp9kb2O1TAQhSMEYi8LL0CBLNHQBMZ_SdwgoQUWpJVooLYmjnOvV0kcPMldbccb0PCEPAm-3GX5KSgsF_OdM3N0iuIxh-ccoH5BXAOHEkR-XIuqhDvFhitpSjC1vFtsQAKUDRfVSfGA6BIAtFH1_eJEClPpSvFN8fU1Di3ucXJhYkhsiNO2XHwaGa3znDxR2Hu27HzC-Zr1MbEZl-CnhdhVWHbsPOFYzpHCcuBadFnrx4CsW7MsMpxYmJaUN5BbB0yM4pqc__7lGzLyKXhisc--a2IOydPD4l6PA_lHN_9p8entm49n78qLD-fvz15dlE4LuZS6RQ4NtK5x2EEr6waUa6EDlNr1la8azmVlWt4po6AWHrTQTrqml1wbNPK0eHn0ndd29J3zhyMHO6cwYrq2EYP9ezKFnd3Gva0bDcbobPDsxiDFz6unxY6BnB8GnHxcyQqltJJgqsOup_-glznvlONlqlGKN5UQmRJHyqVIlHx_ewwHe-jbHvu2uW_7s28LWfTkzxi3kl8FZ0AeAcqjaevT793_sf0BDdm59Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2484418622</pqid></control><display><type>article</type><title>Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source—a series of four cases</title><source>Springer Link</source><creator>Hitzenbichler, Florian ; Mohr, Arno ; Camboni, Daniele ; Simon, Michaela ; Salzberger, Bernd ; Hanses, Frank</creator><creatorcontrib>Hitzenbichler, Florian ; Mohr, Arno ; Camboni, Daniele ; Simon, Michaela ; Salzberger, Bernd ; Hanses, Frank</creatorcontrib><description>We present four cases with Gram-positive bacteremia (pathogens: MRSA n  = 1 , Enterococcus spp. n  = 3) due to an intravascular source (left ventricular assist device: n  = 2, transfemoral aortic valve implantation n  = 1, prosthetic aortic valve: n  = 1) where no curative treatment was available. These patients received indefinite, chronic suppressive (palliative) therapy with dalbavancin (500 mg weekly or 1000 mg biweekly regimens). Outcomes and clinical characteristics are described; treatment was effective in suppression of bacteremia in all patients over several months (range: 1 to more than 12 months), we observed no relevant side effects.</description><identifier>ISSN: 0300-8126</identifier><identifier>EISSN: 1439-0973</identifier><identifier>DOI: 10.1007/s15010-020-01526-0</identifier><identifier>PMID: 32965641</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antibiotics ; Aorta ; Aortic valve ; Bacteremia ; Case Report ; Case reports ; Drug resistance ; Endocarditis ; Family Medicine ; General Practice ; Gram-positive bacteria ; Heart ; Heart valves ; Infectious Diseases ; Internal Medicine ; Medicine ; Medicine &amp; Public Health ; Patients ; Prostheses ; Side effects ; Transplants &amp; implants ; Ventricle</subject><ispartof>Infection, 2021-02, Vol.49 (1), p.181-186</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c523t-5ba1080bc8cad0b37804cb0d0a35cf6e6811369b1d494072e0525c3c8f3159a93</citedby><cites>FETCH-LOGICAL-c523t-5ba1080bc8cad0b37804cb0d0a35cf6e6811369b1d494072e0525c3c8f3159a93</cites><orcidid>0000-0003-4374-2787</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32965641$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hitzenbichler, Florian</creatorcontrib><creatorcontrib>Mohr, Arno</creatorcontrib><creatorcontrib>Camboni, Daniele</creatorcontrib><creatorcontrib>Simon, Michaela</creatorcontrib><creatorcontrib>Salzberger, Bernd</creatorcontrib><creatorcontrib>Hanses, Frank</creatorcontrib><title>Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source—a series of four cases</title><title>Infection</title><addtitle>Infection</addtitle><addtitle>Infection</addtitle><description>We present four cases with Gram-positive bacteremia (pathogens: MRSA n  = 1 , Enterococcus spp. n  = 3) due to an intravascular source (left ventricular assist device: n  = 2, transfemoral aortic valve implantation n  = 1, prosthetic aortic valve: n  = 1) where no curative treatment was available. These patients received indefinite, chronic suppressive (palliative) therapy with dalbavancin (500 mg weekly or 1000 mg biweekly regimens). Outcomes and clinical characteristics are described; treatment was effective in suppression of bacteremia in all patients over several months (range: 1 to more than 12 months), we observed no relevant side effects.</description><subject>Antibiotics</subject><subject>Aorta</subject><subject>Aortic valve</subject><subject>Bacteremia</subject><subject>Case Report</subject><subject>Case reports</subject><subject>Drug resistance</subject><subject>Endocarditis</subject><subject>Family Medicine</subject><subject>General Practice</subject><subject>Gram-positive bacteria</subject><subject>Heart</subject><subject>Heart valves</subject><subject>Infectious Diseases</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Patients</subject><subject>Prostheses</subject><subject>Side effects</subject><subject>Transplants &amp; implants</subject><subject>Ventricle</subject><issn>0300-8126</issn><issn>1439-0973</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kb2O1TAQhSMEYi8LL0CBLNHQBMZ_SdwgoQUWpJVooLYmjnOvV0kcPMldbccb0PCEPAm-3GX5KSgsF_OdM3N0iuIxh-ccoH5BXAOHEkR-XIuqhDvFhitpSjC1vFtsQAKUDRfVSfGA6BIAtFH1_eJEClPpSvFN8fU1Di3ucXJhYkhsiNO2XHwaGa3znDxR2Hu27HzC-Zr1MbEZl-CnhdhVWHbsPOFYzpHCcuBadFnrx4CsW7MsMpxYmJaUN5BbB0yM4pqc__7lGzLyKXhisc--a2IOydPD4l6PA_lHN_9p8entm49n78qLD-fvz15dlE4LuZS6RQ4NtK5x2EEr6waUa6EDlNr1la8azmVlWt4po6AWHrTQTrqml1wbNPK0eHn0ndd29J3zhyMHO6cwYrq2EYP9ezKFnd3Gva0bDcbobPDsxiDFz6unxY6BnB8GnHxcyQqltJJgqsOup_-glznvlONlqlGKN5UQmRJHyqVIlHx_ewwHe-jbHvu2uW_7s28LWfTkzxi3kl8FZ0AeAcqjaevT793_sf0BDdm59Q</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Hitzenbichler, Florian</creator><creator>Mohr, Arno</creator><creator>Camboni, Daniele</creator><creator>Simon, Michaela</creator><creator>Salzberger, Bernd</creator><creator>Hanses, Frank</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4374-2787</orcidid></search><sort><creationdate>20210201</creationdate><title>Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source—a series of four cases</title><author>Hitzenbichler, Florian ; Mohr, Arno ; Camboni, Daniele ; Simon, Michaela ; Salzberger, Bernd ; Hanses, Frank</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c523t-5ba1080bc8cad0b37804cb0d0a35cf6e6811369b1d494072e0525c3c8f3159a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibiotics</topic><topic>Aorta</topic><topic>Aortic valve</topic><topic>Bacteremia</topic><topic>Case Report</topic><topic>Case reports</topic><topic>Drug resistance</topic><topic>Endocarditis</topic><topic>Family Medicine</topic><topic>General Practice</topic><topic>Gram-positive bacteria</topic><topic>Heart</topic><topic>Heart valves</topic><topic>Infectious Diseases</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Patients</topic><topic>Prostheses</topic><topic>Side effects</topic><topic>Transplants &amp; implants</topic><topic>Ventricle</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hitzenbichler, Florian</creatorcontrib><creatorcontrib>Mohr, Arno</creatorcontrib><creatorcontrib>Camboni, Daniele</creatorcontrib><creatorcontrib>Simon, Michaela</creatorcontrib><creatorcontrib>Salzberger, Bernd</creatorcontrib><creatorcontrib>Hanses, Frank</creatorcontrib><collection>SpringerOpen(OpenAccess)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Nursing and Allied Health Source</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hitzenbichler, Florian</au><au>Mohr, Arno</au><au>Camboni, Daniele</au><au>Simon, Michaela</au><au>Salzberger, Bernd</au><au>Hanses, Frank</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source—a series of four cases</atitle><jtitle>Infection</jtitle><stitle>Infection</stitle><addtitle>Infection</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>49</volume><issue>1</issue><spage>181</spage><epage>186</epage><pages>181-186</pages><issn>0300-8126</issn><eissn>1439-0973</eissn><abstract>We present four cases with Gram-positive bacteremia (pathogens: MRSA n  = 1 , Enterococcus spp. n  = 3) due to an intravascular source (left ventricular assist device: n  = 2, transfemoral aortic valve implantation n  = 1, prosthetic aortic valve: n  = 1) where no curative treatment was available. These patients received indefinite, chronic suppressive (palliative) therapy with dalbavancin (500 mg weekly or 1000 mg biweekly regimens). Outcomes and clinical characteristics are described; treatment was effective in suppression of bacteremia in all patients over several months (range: 1 to more than 12 months), we observed no relevant side effects.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>32965641</pmid><doi>10.1007/s15010-020-01526-0</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-4374-2787</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0300-8126
ispartof Infection, 2021-02, Vol.49 (1), p.181-186
issn 0300-8126
1439-0973
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7850995
source Springer Link
subjects Antibiotics
Aorta
Aortic valve
Bacteremia
Case Report
Case reports
Drug resistance
Endocarditis
Family Medicine
General Practice
Gram-positive bacteria
Heart
Heart valves
Infectious Diseases
Internal Medicine
Medicine
Medicine & Public Health
Patients
Prostheses
Side effects
Transplants & implants
Ventricle
title Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source—a series of four cases
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T12%3A33%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dalbavancin%20as%20long-term%20suppressive%20therapy%20for%20patients%20with%20Gram-positive%20bacteremia%20due%20to%20an%20intravascular%20source%E2%80%94a%20series%20of%20four%20cases&rft.jtitle=Infection&rft.au=Hitzenbichler,%20Florian&rft.date=2021-02-01&rft.volume=49&rft.issue=1&rft.spage=181&rft.epage=186&rft.pages=181-186&rft.issn=0300-8126&rft.eissn=1439-0973&rft_id=info:doi/10.1007/s15010-020-01526-0&rft_dat=%3Cproquest_pubme%3E2484418622%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c523t-5ba1080bc8cad0b37804cb0d0a35cf6e6811369b1d494072e0525c3c8f3159a93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2484418622&rft_id=info:pmid/32965641&rfr_iscdi=true